Iveta Kolářová
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Iveta Kolářová has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
- Bohuslav Melichar
Department of Oncology, Faculty of Medicine and Dentistry, Palacký University and University Hospital, Zdravotníků 248/7, 779 00, Olomouc 9, Czech Republic
3 shared publications - Denisa Pohanková
Department of Oncology and Radiotherapy, University Teaching Hospital Hradec Kralove, Charles University, Faculty of Medicine in Hradec Kralove, 500 05 Hradec Kralove, Czech Republic
3 shared publications - Igor Sirák
Department of Oncology and Radiotherapy, University Hospital and Medical Faculty, Hradec Králové, Czech Republic
3 shared publications - Jiří Petera
Department of Oncology and Radiotherapy, Faculty of Medicine in Hradec Králové and University Hospital Hradec Králové, Charles University, 500 05 Hradec Králové, Czech Republic
3 shared publications - Kateřina Horáčková
University of Pardubice
3 shared publications - Milan Vošmik
Department of Oncology and Radiotherapy, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic
3 shared publications
Latest Publications
- Open Access
- 12 January 2026
- Published by Elsevier in The Breast
- Vol. 85, 104699
Timing of final oncologist visit and systemic treatment use near the end of life in pretreated patients with metastatic triple-negative breast cancer: a multinational cohort study
- 12 January 2026
- Published by Elsevier in The Breast
- Vol. 85, 104699
Open AccessTiming of final oncologist visit and systemic treatment use near the end of life in pretreated patients with metastatic triple-negative breast cancer: a multinational cohort study
- Open Access
- 28 February 2024
- Published by Solen s.r.o. in Onkologie
- Vol. 18 (1) , 39-42
Changes in approach to locoregional treatment of early breast cancer
Volba optim?ln?ho terapeutick?ho postupu u nemocn?ch s karcinomem prsu p?edstavuje n?ro?n? ?kol. Onemocn?n? je tvo?eno celou ?adou subtyp? s rozd?lnou biologickou charakteristikou a r?znou progn?zou a m??e se vyskytovat i u ?en star??ho v?ku, ... Volba optim?ln?ho terapeutick?ho postupu u nemocn?ch s karcinomem prsu p?edstavuje n?ro?n? ?kol. Onemocn?n? je tvo?eno celou ?adou subtyp? s rozd?lnou biologickou charakteristikou a r?znou progn?zou a m??e se vyskytovat i u ?en star??ho v?ku, ...
- 28 February 2024
- Published by Solen s.r.o. in Onkologie
- Vol. 18 (1) , 39-42
Open AccessChanges in approach to locoregional treatment of early breast cancer
Volba optim?ln?ho terapeutick?ho postupu u nemocn?ch s karcinomem prsu p?edstavuje n?ro?n? ?kol. Onemocn?n? je tvo?eno celou ?adou subtyp? s rozd?lnou biologickou charakteristikou a r?znou progn?zou a m??e se vyskytovat i u ?en star??ho v?ku, ... Volba optim?ln?ho terapeutick?ho postupu u nemocn?ch s karcinomem prsu p?edstavuje n?ro?n? ?kol. Onemocn?n? je tvo?eno celou ?adou subtyp? s rozd?lnou biologickou charakteristikou a r?znou progn?zou a m??e se vyskytovat i u ?en star??ho v?ku, ...
- Open Access
- 24 February 2024
- Published by MDPI AG in Current Oncology
- Vol. 31 (3) , 1207-1220
The Role of Adjuvant Radiotherapy in the Treatment of Breast Cancer
The role of postmastectomy radiotherapy and regional nodal irradiation after radical mastectomy is defined in high-risk patients with locally advanced tumors, positive margins, and unfavorable biology. The benefit of postmastectomy radiotherapy in intermediate-risk patients (T3N0 tumors) remains a matter of controversy. It has been demonstrated that radiotherapy after breast-conserving surgery lowers the locoregional recurrence rate compared with surgery alone and improves the overall survival rate. In patients with four or more positive lymph nodes or extracapsular extension, regional lymph node irradiation is indicated regardless of the surgery type (breast-conserving surgery or mastectomy). Despite the consensus that patients with more than three positive lymph nodes should be treated with radiotherapy, there is controversy regarding the recommendations for patients with one to three involved lymph nodes. In patients with N0 disease with negative findings on axillary surgery, there is a trend to administer regional lymph node irradiation in patients with a high risk of recurrence. In patients treated with neoadjuvant systemic therapy and mastectomy, adjuvant radiotherapy should be administered in cases of clinical stage III and/or ≥ypN1. In patients treated with neoadjuvant systemic therapy and breast-conserving surgery, postoperative radiotherapy is indicated irrespective of pathological response.
- 24 February 2024
- Published by MDPI AG in Current Oncology
- Vol. 31 (3) , 1207-1220
Open AccessThe Role of Adjuvant Radiotherapy in the Treatment of Breast Cancer
The role of postmastectomy radiotherapy and regional nodal irradiation after radical mastectomy is defined in high-risk patients with locally advanced tumors, positive margins, and unfavorable biology. The benefit of postmastectomy radiotherapy in intermediate-risk patients (T3N0 tumors) remains a matter of controversy. It has been demonstrated that radiotherapy after breast-conserving surgery lowers the locoregional recurrence rate compared with surgery alone and improves the overall survival rate. In patients with four or more positive lymph nodes or extracapsular extension, regional lymph node irradiation is indicated regardless of the surgery type (breast-conserving surgery or mastectomy). Despite the consensus that patients with more than three positive lymph nodes should be treated with radiotherapy, there is controversy regarding the recommendations for patients with one to three involved lymph nodes. In patients with N0 disease with negative findings on axillary surgery, there is a trend to administer regional lymph node irradiation in patients with a high risk of recurrence. In patients treated with neoadjuvant systemic therapy and mastectomy, adjuvant radiotherapy should be administered in cases of clinical stage III and/or ≥ypN1. In patients treated with neoadjuvant systemic therapy and breast-conserving surgery, postoperative radiotherapy is indicated irrespective of pathological response.
- Open Access
- 18 January 2024
- Published by MDPI AG in Preprints.org
The Role of Adjuvant Radiotherapy in the Treatment of Breast Cancer
The role of postmastectomy radiotherapy and regional nodal irradiation after radical mastectomy is defined in high-risk patients with locally advanced tumors, positive margins, and unfavorable biology. The benefit of postmastectomy radiotherapy in intermediate-risk patients (T3N0 tumors) remains a matter of controversy. It has been demonstrated that radiotherapy after breast-conserving surgery lowers the locoregional recurrence rate compared with surgery alone and improves the overall survival rate. In patients with 4 or more positive lymph nodes or extracapsular extension regional lymph node irradiation is indicated regardless of the surgery type (breast-conserving surgery or mastectomy). Despite the consensus that patients with more than 3 positive lymph nodes should be treated with radiotherapy, there is a controversy regarding the recommendations for patients with one to three involved lymph nodes. In patients with N0 disease with negative findings on axillary surgery, there is a trend to administer regional lymph node irradiation in patients with a high risk of recurrence. In patients treated with neoadjuvant systemic therapy and mastectomy, adjuvant radiotherapy should be administered in case of clinical stage III and/or ≥ypN1. In patients treated with neoadjuvant systemic therapy and breast-conserving surgery, postoperative radiotherapy is indicated irrespective of pathological response.
- 18 January 2024
- Published by MDPI AG in Preprints.org
Open AccessThe Role of Adjuvant Radiotherapy in the Treatment of Breast Cancer
The role of postmastectomy radiotherapy and regional nodal irradiation after radical mastectomy is defined in high-risk patients with locally advanced tumors, positive margins, and unfavorable biology. The benefit of postmastectomy radiotherapy in intermediate-risk patients (T3N0 tumors) remains a matter of controversy. It has been demonstrated that radiotherapy after breast-conserving surgery lowers the locoregional recurrence rate compared with surgery alone and improves the overall survival rate. In patients with 4 or more positive lymph nodes or extracapsular extension regional lymph node irradiation is indicated regardless of the surgery type (breast-conserving surgery or mastectomy). Despite the consensus that patients with more than 3 positive lymph nodes should be treated with radiotherapy, there is a controversy regarding the recommendations for patients with one to three involved lymph nodes. In patients with N0 disease with negative findings on axillary surgery, there is a trend to administer regional lymph node irradiation in patients with a high risk of recurrence. In patients treated with neoadjuvant systemic therapy and mastectomy, adjuvant radiotherapy should be administered in case of clinical stage III and/or ≥ypN1. In patients treated with neoadjuvant systemic therapy and breast-conserving surgery, postoperative radiotherapy is indicated irrespective of pathological response.
- Open Access
Special Techniques of Adjuvant Breast Carcinoma Radiotherapy
Modern radiotherapy techniques are designed to permit reduced irradiation of healthy tissue, resulting in a diminished risk of adverse effects and shortened recovery times. Several randomized studies have demonstrated the benefits of increased dosage to the tumor bed area in combination with whole breast irradiation (WBI). Conventional WBI treatment following breast-conserving procedures, which required 5–7 weeks of daily treatments, has been reduced to 3–4 weeks when using hyperfractionated regimens. The dosage administration improves local control, albeit with poorer cosmesis. The method of accelerated partial breast irradiation (APBI) shortens the treatment period whilst reducing the irradiated volume. APBI can be delivered using intraoperative radiation, brachytherapy, or external beam radiotherapy. Currently available data support the use of external beam partial breast irradiation in selected patients. Modern radiotherapy techniques make it possible to achieve favorable cosmesis in most patients undergoing immediate breast reconstruction surgery, and studies confirm that current methods of external beam radiation allow an acceptable coverage of target volumes both in the reconstructed breast and in the regional lymphatic nodes.
Open AccessSpecial Techniques of Adjuvant Breast Carcinoma Radiotherapy
Modern radiotherapy techniques are designed to permit reduced irradiation of healthy tissue, resulting in a diminished risk of adverse effects and shortened recovery times. Several randomized studies have demonstrated the benefits of increased dosage to the tumor bed area in combination with whole breast irradiation (WBI). Conventional WBI treatment following breast-conserving procedures, which required 5–7 weeks of daily treatments, has been reduced to 3–4 weeks when using hyperfractionated regimens. The dosage administration improves local control, albeit with poorer cosmesis. The method of accelerated partial breast irradiation (APBI) shortens the treatment period whilst reducing the irradiated volume. APBI can be delivered using intraoperative radiation, brachytherapy, or external beam radiotherapy. Currently available data support the use of external beam partial breast irradiation in selected patients. Modern radiotherapy techniques make it possible to achieve favorable cosmesis in most patients undergoing immediate breast reconstruction surgery, and studies confirm that current methods of external beam radiation allow an acceptable coverage of target volumes both in the reconstructed breast and in the regional lymphatic nodes.